Table 1

Baseline demographic and clinical characteristics of patients

Arm A (active control), oral ciprofloxacin/inhaled colistin (n=105)Arm B (test treatment), oral ciprofloxacin/inhaled tobramycin (n=118)
Age in years, median (IQR)7.45 (1–25.5)7.64 (1–35.2)
Gender, n (%)
 Female53 (50.5)54 (45.8)
 Male52 (49.5)64 (54.2)
Cystic fibrosis genotype, n (%)
 F508del homozygotes25 (23.8)29 (24.5)
 F508del compound heterozygotes44 (41.9)53 (44.9)
 Other genotype36 (34.3)36 (30.6)
Coinfection with other pathogens at baseline, n (%)
Staphylococcus aureus 62 (59)63 (53.5)
 Methicillin-resistant S aureus 7 (6)2 (1.6)
Haemophilus influenzae 10 (9.5)12 (10)
Streptococcus pneumoniae 02 (1.6)
Pseudomonas aeruginosa infection, n (%)
 First-ever infection57 (54.3)64 (54.2)
 Previously infected48 (45.7)54 (45.8)
FEV1 (% of predicted)
 Mean (±SD)93.1 (±23.1)91.8 (±19.1)
 Patients able to perform spirometry, n (%)60 (57.1)68 (57.6)
Age and FEV1 group, n (%)
 ≤5 years36 (34.3)41 (34.8)
 >5–12 years, FEV1<70%9 (8.6)11 (9.3)
 >5–12 years, FEV1>70%32 (30.4)35 (29.7)
 >12 years, FEV1<70%5 (4.8)5 (4.2)
 >12 years, FEV1>70%23 (21.9)26 (22)
  • FEV1, forced expiratory volume in 1 s.